(Credit: Associated Press photo)
Johnson & Johnson announced Friday that Sandra (Sandi) E. Peterson, group worldwide chairman for Johnson & Johnson, has announced her plans to retire from J&J effective October 1, 2018.
During her career at Johnson & Johnson, Peterson exercised strong portfolio discipline in the businesses she has led, clarifying priority markets and segments, and shepherding numerous deals, acquisitions and divestitures. During her tenure, the Consumer business performance showed solid improvement, the U.S. OTC business was restored to growth, and the Vision Care business regained market leadership in contact lenses and has become a leader in eye health.
In the past year, the Medical Device sector has made progress strengthening its foundation to improve performance and accelerate growth. Sandi has been instrumental in developing new partnerships in the areas of data science and technology for J&J.
Peterson joined Johnson & Johnson in December of 2012. Prior to joining the company, she was chairman and chief executive officer of Bayer CropScience AG in Germany. She had previously served as CEO of Bayer Medical Care and president of Bayer HealthCare AG’s Diabetes Care Division. Earlier, she held leadership roles at Medco Health Solutions (previously known as Merck-Medco), Nabisco, Whirlpool Corporation, and McKinsey & Company.
Peterson is presently a member of the board of directors of Microsoft, and a member of the Board of Trustees of the Institute for Advanced Study, one of the world’s leading centers for theoretical research and intellectual inquiry. She also is a Trustee of The American Academy in Berlin, a research and cultural institution focused on fostering a greater understanding and dialogue between citizens of the U.S. and Germany.
The company has separately announced a series of additional leadership changes to ensure seamless transition in the leadership of Peterson’s areas of accountability within the business.
Specifically:
- Joaquin Duato, executive vice president, worldwide chairman, pharmaceuticals, and Dr. Paul Stoffels, executive vice president, chief scientific officer of Johnson & Johnson have been appointed to the position of vice chairman of the executive committee, effective July 2, 2018. Duato and Stoffels will continue to report to Alex Gorsky, chairman of the board and chief executive officer of Johnson & Johnson.
- In his role as vice chairman of the executive committee, Duato will be responsible for the Pharmaceuticals and Consumer sectors, as well as Supply Chain, IT, Global Services, and the Health and Wellness businesses.
- In his role as vice chairman of the executive committee, Stoffels will be responsible for Pharmaceutical Research & Development, Global Public Health, the Office of the Chief Medical Officer, External Innovation, Pharmaceuticals Business Development, and Healthcare Technology.
- Ashley McEvoy, company group chairman, consumer medical devices, has been appointed executive vice president, worldwide chairman, medical devices, effective July 2, 2018. She will report to Gorsky and become a member of the executive committee.
- Jennifer Taubert, company group chairman, the Americas, pharmaceuticals, has been appointed executive vice president, worldwide chairman, pharmaceuticals and named to the executive committee, effective July 2, 2018. She will report to Duato.
- Kathy Wengel, worldwide vice president, Johnson & Johnson supply chain has been appointed executive vice president, chief global supply chain officer, and named to the executive committee, effective July 2, 2018. She will report to Duato.
- Michael Sneed, worldwide vice president, global corporate affairs and chief communication officer, will become executive vice president, global corporate affairs and chief communication officer and a member of the executive committee, effective July 2, 2018. Sneed will also assume responsibility for the global design group. He will continue to report to Gorsky.
“These appointments recognize the enormous talent among the senior leadership team of Johnson & Johnson, and will ensure our continued focus on delivering on our commitments to patients, consumers, employees, our communities and our shareholders,” said Gorsky.
In addition, as previously announced Joseph Wolk, vice president of Johnson & Johnson investor relations, has been appointed executive vice president, chief financial officer and a member of the executive committee effective July 1, 2018.
(Source: Johnson & Johnson)
Filed Under: Drug Discovery
